You are here

Nurses Develop Tool to Reduce Hospital Readmissions

Form identifies high-risk patients

Nurses at California Hospital Medical Center in Los Angeles have created a new tool to help reduce hospital readmissions, according to a report posted on

“We were looking for a way to improve on our generic readmission checklist that is completed on a patient’s admission to the hospital,” said nurse manager Gladys Castro, RN. “The medical/surgical unit has the highest volume of readmissions, so we formed a committee to develop a tool that would identify risk factors for patient readmission.”

Within two weeks the committee had developed a high-risk readmission form, which is filled out during a patient’s admission to the hospital. The tool includes questions that assess each patient’s mobility, risk of falls, whether they use oxygen, age, and other factors. If a patient is identified as being at high risk for readmission, then the admitting nurse will put in an order for a case manager to review the case.

More than a year after its introduction, the readmission form has shown promising results, Castro said. Staff compliance has risen from 33% when the form was first introduced to 98%.

The high-risk readmission form is also used during the medical/surgical staff’s morning huddles to address any issues or problems that may have surfaced since a patient was first admitted.

“As part of our commitment to patient-centered care, we are using the form to look at what the patients need upon admission to the hospital, whether it’s chronic-disease education, oxygen, or help getting to their appointments or getting their medications filled,” Castro said.

Source:; December 23, 2015.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks